For the year ending 2025-12-31, KYMR had $236,761K increase in cash & cash equivalents over the period. -$234,340K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -311,351 |
| Stock-based compensation expense | 59,904 |
| Impairment of long-lived assets | 3,856 |
| Depreciation and amortization | 8,313 |
| Premiums and discounts on available for sale marketable securities | -8,879 |
| Prepaid expenses and other assets | 2,361 |
| Accounts receivable | 0 |
| Contract asset | -947 |
| Accounts payable | -1,974 |
| Accrued expenses and other current liabilities | 7,387 |
| Deferred revenue | 20,789 |
| Operating lease right-of-use assets | -2,666 |
| Operating lease liabilities | -5,042 |
| Other non-current assets | 7,164 |
| Other non-current liabilities | 18 |
| Net cash used in operating activities | -232,891 |
| Purchase of property and equipment, net | 1,449 |
| Purchase of marketable securities | 1,007,628 |
| Maturities of marketable securities | 488,016 |
| Net cash provided by (used in) investing activities | -521,061 |
| Issuance of common stock and accompanying pre-funded warrants from january 2024 public offering, net of issuance costs of 14.9 million | 0 |
| Proceeds from issuance of common stock through at-the market sales agreement, net of issuance costs of 1.2 million | 0 |
| Issuance of common stock and accompanying pre-funded warrants from august 2024 public offering, net of issuance costs of 12.2 million | 0 |
| Issuance of common stock and accompanying pre-funded warrants from june 2025 public offering, net of issuance costs of 15.7 million | -272,671 |
| Issuance of common stock from december 2025 public offering, net of issuance costs of 36.2 million | -656,230 |
| Proceeds from stock option exercises | 61,621 |
| Proceeds from employee stock purchase plan | 1,685 |
| Payments on financing leases | 1,494 |
| Net cash provided by financing activities | 990,713 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 236,761 |
| Cash, cash equivalents and restricted cash at beginning of period | 126,050 |
| Cash, cash equivalents and restricted cash at end of period | 362,811 |
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)